How should an adult with stage 3–4 chronic kidney disease (eGFR 15–59 mL/min) and diastolic heart failure with preserved ejection fraction be managed?

Management of Diastolic Dysfunction (HFpEF) in Adults with Stage 3–4 CKD

Start an SGLT2 inhibitor (dapagliflozin 10 mg daily) immediately as first-line disease-modifying therapy, combined with loop diuretics for congestion, in all patients with HFpEF and stage 3–4 CKD (eGFR 15–59 mL/min/1.73 m²). 1, 2, 3

Initial Assessment and Stabilization

Volume Status Evaluation

• Assess for signs of congestion: jugular venous distention, pulmonary crackles (rales), peripheral edema, orthopnea, and paroxysmal nocturnal dyspnea 2, 4
• Monitor daily weights: sudden increases (>2 kg over 2–3 days) indicate fluid retention requiring diuretic adjustment 5
• Check natriuretic peptides (BNP or NT-proBNP) to confirm elevated filling pressures and guide therapy 1

Baseline Laboratory Assessment

• Measure eGFR and serum creatinine to stage CKD and establish baseline renal function 1, 3
• Check serum potassium before initiating any RAAS inhibitors or mineralocorticoid receptor antagonists 1
• Assess urine albumin-to-creatinine ratio (UACR) to quantify proteinuria and track CKD progression 1

First-Line Pharmacotherapy

SGLT2 Inhibitors (Class 2a Recommendation)

Dapagliflozin 10 mg once daily is the cornerstone of HFpEF treatment in patients with eGFR ≥30 mL/min/1.73 m² (covering stage 3A, 3B, and most stage 4 CKD). 1, 2, 3

• Evidence base: DELIVER trial demonstrated 18% reduction in composite cardiovascular death or heart failure hospitalization (HR 0.82; 95% CI 0.73–0.92) and 23% reduction in heart failure hospitalizations (HR 0.77; 95% CI 0.67–0.89) 2
• Renal benefits: SGLT2 inhibitors reduce sustained eGFR decline, progression to end-stage kidney disease, and cardiovascular death in CKD patients 1, 3
• Timing: Initiate once hemodynamically stable; benefits appear within weeks and are independent of diabetes status 2, 4
• No titration required: Fixed 10 mg dose with minimal blood pressure or heart rate effects 2
• Monitoring: Expect modest eGFR decline (3–10%) upon initiation; do not discontinue unless acute kidney injury is suspected 1

Loop Diuretics for Congestion

Use the lowest effective dose of furosemide (or equivalent loop diuretic) to achieve and maintain euvolemia. 1, 2, 4

• Initial dosing for acute congestion: 40–80 mg IV furosemide (or double the chronic oral dose) 4
• Escalation strategy if inadequate response within 6–12 hours: 4
  • Double the IV loop diuretic dose, OR
  • Add thiazide diuretic (e.g., hydrochlorothiazide 25–50 mg daily) for sequential nephron blockade, OR
  • Add IV acetazolamide 500 mg once daily
• Target: Weight loss of 1–2 kg over several days until orthopnea and edema resolve 5
• Maintenance: Taper to lowest dose that maintains euvolemia to avoid excessive diuresis 2, 4
• Monitoring: Check electrolytes, BUN, and creatinine every 12–24 hours during aggressive diuresis, then within one week after dose changes 4, 5

Blood Pressure Management

Target systolic BP <130 mmHg and diastolic <80 mmHg using agents with heart failure benefits. 2, 4

• First-line after volume optimization: ACE inhibitor or ARB (e.g., lisinopril 10–40 mg daily or losartan 50–100 mg daily) 2, 4
  • These agents modestly reduce heart failure hospitalizations in HFpEF, though they do not provide the mortality benefit seen in HFrEF 4
• Loop diuretics are the only antihypertensive class that reliably addresses fluid overload in heart failure and should remain the foundation of volume management 4
• Hypertension is present in 60–89% of HFpEF patients and represents the most important modifiable risk factor 4

Additional Pharmacologic Options

Mineralocorticoid Receptor Antagonist (Class 2b)

Consider spironolactone 12.5–25 mg daily, particularly in patients with LVEF in the lower preserved range (40–50%). 1, 2, 4

• Evidence: TOPCAT trial showed 17% reduction in heart failure hospitalizations (HR 0.83; 95% CI 0.69–0.99), with greater benefit at LVEF ≈45% 2, 4
• Initiation criteria: Creatinine <2.5 mg/dL (men) or <2.0 mg/dL (women), eGFR >30 mL/min/1.73 m², and potassium <5.0 mmol/L 4
• Monitoring: Check potassium and creatinine within 3 days of initiation, then weekly for one month, then monthly 4, 5
• Combination benefit: SGLT2 inhibitors lower the risk of MRA-related hyperkalemia and promote treatment persistence 1

Angiotensin Receptor-Neprilysin Inhibitor (Class 2b)

Sacubitril/valsartan may be considered for women and patients with LVEF 45–57%. 2, 4

• Evidence: PARAGON-HF showed trend toward benefit (rate ratio 0.87; 95% CI 0.75–1.01; p=0.06), with greater effect in LVEF 45–57% (RR 0.78; 95% CI 0.64–0.95) and women (RR 0.73; 95% CI 0.59–0.90) 2, 4
• Advantage in CKD: ARNI carries lower hyperkalemia risk than ACE inhibitors when combined with MRA 1

Management of Key Comorbidities

Diabetes Mellitus

Prioritize SGLT2 inhibitors for dual glycemic and heart failure benefits. 2, 5

• Second-line for glucose control: GLP-1 receptor agonist (e.g., semaglutide) if BMI ≥30 kg/m² and additional weight loss is desired 1, 2
• Avoid thiazolidinediones (pioglitazone, rosiglitazone), which promote fluid retention and worsen heart failure 2, 5
• Avoid DPP-4 inhibitors saxagliptin and alogliptin, which increase heart failure hospitalization risk 2

Atrial Fibrillation (if present)

Use cardioselective beta-blockers for rate control, targeting resting heart rate <110 bpm. 4

• Rationale: Beta-blockers slow heart rate, extend diastolic filling time, and lower left ventricular diastolic pressures 4
• Anticoagulation: Initiate when CHA₂DS₂-VASc ≥2 per standard stroke prevention guidelines 4
• Avoid nondihydropyridine calcium channel blockers (diltiazem, verapamil), which have negative inotropic effects and increase heart failure worsening 2, 4, 5

Renal Function Monitoring in CKD

Expected Changes with Therapy

• Tolerate acute eGFR decreases ≤30% after initiating RAAS inhibitors or SGLT2 inhibitors; do not discontinue prematurely 1
• If >30% decline in eGFR: ensure euvolemia (adjust diuretic dose), discontinue nonessential nephrotoxic agents, and evaluate alternative etiologies 1
• SGLT2 inhibitors can be initiated at eGFR as low as 20 mL/min/1.73 m² and continued as renal function declines 1

Hyperkalemia Management (K⁺ >5.0 mEq/L)

• Recheck elevated potassium before making therapeutic changes 1
• Consider potassium binders (patiromer or sodium zirconium cyclosilicate) to facilitate ongoing use of RAAS inhibitors and MRAs 1
• Dietary potassium restriction 1

Ongoing Monitoring

• Assess eGFR and albuminuria at least annually to track CKD progression 1
• Monitor natriuretic peptides (NT-proBNP or BNP) to guide heart failure therapy 1
• Regularly assess volume status, renal function, and electrolytes to guide treatment adjustments 2

Non-Pharmacologic Interventions

Exercise Training (Class 1 Recommendation)

Prescribe supervised aerobic exercise 3 sessions per week for 1–8 months at 40–90% of peak capacity. 2, 4

• Benefits: Improves functional capacity by 12–14% and quality of life with effect sizes comparable to or exceeding those in HFrEF 2, 4
• Mechanism: Addresses peripheral vascular, skeletal muscle, and cardiac abnormalities contributing to exercise intolerance 4

Dietary Sodium Restriction

Recommend sodium intake <2–3 g per day to lessen congestion and improve diuretic efficacy 2, 4, 5

Critical Medications to Avoid

• Nondihydropyridine calcium channel blockers (diltiazem, verapamil): negative inotropic effects and increased heart failure worsening 2, 4, 5
• Nitrates: associated with signal of harm in HFpEF 2, 4
• Thiazolidinediones: promote fluid retention and heart failure exacerbation 2, 5
• Saxagliptin and alogliptin: increase heart failure hospitalization risk 2

Advanced Therapies for Refractory Disease

When Standard Therapy Fails

• Ultrafiltration may be employed as last-resort strategy for recurrent hospitalizations despite optimal diuretic therapy 2, 4
• Implantable pulmonary artery pressure monitors can guide volume optimization in selected patients with prior decompensated admissions 2, 4
• Referral to advanced heart failure specialist for multidisciplinary evaluation of refractory HFpEF 2, 4

Common Pitfalls to Avoid

• Do not discontinue SGLT2 inhibitors or RAAS inhibitors for modest eGFR decline (≤30%) in stable patients; renal function often stabilizes over time 1, 6
• Avoid excessive diuresis leading to hypotension and worsening renal function, which compromises tolerance of guideline-directed therapies 2, 4, 5
• Do not delay SGLT2 inhibitor initiation; benefits appear within weeks and are independent of diabetes status 2, 4
• Do not treat HFpEF patients identically to HFrEF patients; response to therapies differs significantly between these populations 2
• Do not overlook comorbidity management (hypertension, diabetes, obesity, atrial fibrillation), which significantly impacts outcomes 2, 4

Evidence Gaps

No single pharmacologic agent has demonstrated definitive mortality reduction as a standalone endpoint in HFpEF. 2 The principal benefit of SGLT2 inhibitors is reduction in heart failure hospitalizations, which drives improvement in composite cardiovascular outcomes. 2